Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 42
Filter
Add more filters

Publication year range
1.
Redox Biol ; 56: 102420, 2022 10.
Article in English | MEDLINE | ID: mdl-35969998

ABSTRACT

Vitamin C (VC, l-ascorbic acid) is an essential nutrient that plays a key role in metabolism and functions as a potent antioxidant in regulating the S-nitrosylation and denitrosylation of target proteins. The precise function of VC deprivation in glucose homeostasis is still unknown. In the absence of L-gulono-1,4-lactone oxidoreductase, an essential enzyme for the last step of VC synthesis, VC deprivation resulted in persistent hypoglycemia and subsequent impairment of cognitive functions in female but not male mouse pups. The cognitive disorders caused by VC deprivation were largely reversed when these female pups were given glucose. VC deprivation-induced S-nitrosylation of glycogen synthase kinase 3ß (GSK3ß) at Cys14, which activated GSK3ß and inactivated glycogen synthase to decrease glycogen synthesis and storage under the feeding condition, while VC deprivation inactivated glycogen phosphorylase to decrease glycogenolysis under the fasting condition, ultimately leading to hypoglycemia and cognitive disorders. Treatment with Nω-Nitro-l-arginine methyl ester (l-NAME), a specific inhibitor of nitric oxide synthase, on the other hand, effectively prevented S-nitrosylation and activation of GSK3ß in female pups in response to the VC deprivation and reversed hypoglycemia and cognitive disorders. Overall, this research identifies S-nitrosylation of GSK3ß and subsequent GSK3ß activation as a previously unknown mechanism controlling glucose homeostasis in female pups in response to VC deprivation, implying that VC supplementation in the prevention of hypoglycemia and cognitive disorders should be considered in the certain groups of people, particularly young females.


Subject(s)
Ascorbic Acid Deficiency , Cognition , Hypoglycemia , Neurocognitive Disorders , Animals , Antioxidants , Ascorbic Acid/pharmacology , Ascorbic Acid Deficiency/complications , Ascorbic Acid Deficiency/metabolism , Female , Glucose/metabolism , Glycogen/metabolism , Glycogen Phosphorylase , Glycogen Synthase/metabolism , Glycogen Synthase Kinase 3 beta , Humans , Hypoglycemia/etiology , Hypoglycemia/metabolism , Lactones , Mice , NG-Nitroarginine Methyl Ester/pharmacology , Neurocognitive Disorders/etiology , Neurocognitive Disorders/metabolism , Nitric Oxide Synthase
2.
J Invest Surg ; 34(12): 1297-1303, 2021 Dec.
Article in English | MEDLINE | ID: mdl-32727232

ABSTRACT

BACKGROUND: Perioperative neurocognitive disorders (PND) resulting from cardiac surgery is a complication with high morbidity and mortality. However, the pathogenesis is unknown. METHODS: For the sake of investigating the risk factors and mechanism of PND, we collected the characteristics and neurological scores of patients undergoing cardiac surgery in the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University and Affiliated Hospital of Southwest Medical University from Jan 1, 2016 to Dec 11, 2018. RESULTS: We found that age and left atrial thrombus are independent risk factors for PND after cardiac surgery. Furthermore, the serum of 29 patients was collected on the 7th day after cardiac surgery for detecting the expression of lncRNA-MYL2-2 and miR-124-3p. Increased lncRNA-MYL2-2 and decreased miR-124-3p in serum were associated with the decline of patients' cognition. CONCLUSIONS: LncRNA-MYL2-2 and miRNA-124-3p may jointly participate in the occurrence and development of PND after cardiac surgery. These important findings are advantaged to further understand the pathogenesis of PND and prevent it, provide new biomarkers for the diagnosis and monitoring of PND.


Subject(s)
Cardiac Surgical Procedures , MicroRNAs , Neurocognitive Disorders , RNA, Long Noncoding , Biomarkers , Cardiac Surgical Procedures/adverse effects , Humans , MicroRNAs/genetics , Neurocognitive Disorders/diagnosis , Neurocognitive Disorders/epidemiology , Neurocognitive Disorders/etiology , RNA, Long Noncoding/genetics
3.
Contemp Clin Trials ; 98: 106150, 2020 11.
Article in English | MEDLINE | ID: mdl-32942053

ABSTRACT

The symptom burden of HIV-associated neurocognitive disorder (HAND) is high among older individuals, and treatment options are limited. Mindfulness-based stress reduction (MBSR) has potential to improve neurocognitive performance, psychosocial wellbeing, and quality of life, but empirical studies in this growing vulnerable population are lacking. In this trial, participants (N = 180) age 55 and older who are living with HIV infection, are on combination antiretroviral therapy with suppressed viral loads, and yet continue to experience behavioral and cognitive symptoms of HAND, are randomized to MBSR or to a waitlist control arm that receives MBSR following a 16-week period of standard care. Primary outcomes (attention, executive function, stress, anxiety, depression, everyday functioning, quality of life) and potential mediators (affect, mindfulness) and moderators (social support, loneliness) are assessed at baseline and weeks 8, 16, and 48 in both groups, with an additional assessment at week 24 (post-MBSR) in the crossover control group. Assessments include self-report and objective measures (e.g., neuropsychological assessment, neurological exam, clinical labs). In addition, a subset of participants (n = 30 per group) are randomly selected to undergo fMRI to evaluate changes in functional connectivity networks and their relationship to changes in neuropsychological outcomes. Forthcoming findings from this randomized controlled trial have the potential to contribute to a growing public health need as the number of older adults with HAND is expected to rise.


Subject(s)
HIV Infections , Mindfulness , Aged , HIV Infections/complications , HIV Infections/therapy , Humans , Middle Aged , Neurocognitive Disorders/etiology , Neurocognitive Disorders/therapy , Quality of Life , Randomized Controlled Trials as Topic , Stress, Psychological/therapy , Treatment Outcome
4.
Surgery ; 168(1): 147-154, 2020 07.
Article in English | MEDLINE | ID: mdl-32178865

ABSTRACT

BACKGROUND: Cardiopulmonary bypass may be associated with postoperative neurocognitive dysfunction; however, risk factors have not been clearly identified. We hypothesize that lower hematocrit levels are correlated with postoperative neurocognitive dysfunction. METHODS: A total of 30 patients underwent cardiac operations utilizing cardiopulmonary bypass and screening for neurocognitive dysfunction preoperatively and on postoperative day 4. Patients were analyzed according to hematocrit preoperatively, 6 hours postoperatively, and on postoperative day 4, and whether they received intra or postoperative transfusions of packed red blood cells. Neurocognitive data is presented as a difference in Repeatable Battery for the Assessment of Neuropsychological Status standardized score from baseline to postoperative day 4 and analyzed by unpaired two-tailed Spearman test and unpaired Mann-Whitney U test. RESULTS: There was a significant correlation between patients with lower hematocrit before surgery and a decline in neurocognitive function at postoperative day 4 (P < .05). All patients experienced a decrease in hematocrit during their hospital stay, but the hematocrit 6 hours postoperatively and postoperative day 4 did not impact cognition. Receiving a transfusion was also not associated with neurocognitive dysfunction. Patients with low hematocrit preoperatively had a consistently lower hematocrit throughout their stay. Prolonged total length of stay was also significantly associated with neurocognitive decline. CONCLUSION: A lower preoperative hematocrit and prolonged length of hospital stay are correlated with neurocognitive decline after cardiac surgery utilizing cardiopulmonary bypass.


Subject(s)
Anemia/complications , Cardiopulmonary Bypass/adverse effects , Neurocognitive Disorders/etiology , Postoperative Complications/etiology , Aged , Blood Transfusion, Autologous , Cardiac Surgical Procedures , Female , Hematocrit , Humans , Length of Stay , Male , Middle Aged , Prospective Studies
5.
Undersea Hyperb Med ; 45(1): 83-87, 2018.
Article in English | MEDLINE | ID: mdl-29571236

ABSTRACT

Neuropsychiatric sequelae have been reported in 15%-45% of survivors of carbon monoxide (CO) poisoning. Hyperbaric oxygen (HBO2) therapy reduces the incidence of cognitive and neurological a dysfunction. The efficacy of providing HBO2 beyond the first one to two days after initial insult is unknown. However, some evidence exists for the benefit of this treatment. We report on treating a patient 14 months after CO injury, who responded with markedly improved neurologic status. A 27-year-old scholar was found comatose due to CO poisoning (carboxyhemoglobin = 31.7%). He received five acute HBO2 treatments. After discharge, he developed chorea, Parkinsonism, dystonia, memory loss, slowed processing speed and verbal fluency, leaving him disabled. After the patient reached a clinical plateau, HBO2 was tried again at 90 minutes at 2.4 ATA plus air breaks. Neuropsychological testing was performed at baseline and after each 20 HBO2 cycles, five of which were performed during the period from 14-22 months after CO exposure. After the first 20 treatments, Parkinsonism and dystonia improved. After 40 sessions, further improvements were seen on mental speed, verbal fluency, and fine motor movements. The outcome following 100 treatments was that the patient regained independence, including the ability to drive and to become gainfully employed. Our case calls into question the concept that HBO2 therapy has no role during the chronic phase of CO brain injury. Randomized clinical trials should be considered to evaluate the therapeutic efficacy of HBO2 in patients with neurological sequelae following CO injury.


Subject(s)
Carbon Monoxide Poisoning/complications , Hyperbaric Oxygenation/methods , Neurocognitive Disorders/therapy , Recovery of Function , Adult , Dystonia/etiology , Dystonia/therapy , Humans , Hyperbaric Oxygenation/statistics & numerical data , Independent Living , Male , Neurocognitive Disorders/etiology , Neuropsychological Tests , Parkinsonian Disorders/etiology , Parkinsonian Disorders/therapy , Retreatment/methods , Retreatment/statistics & numerical data , Suicide, Attempted , Time Factors , Treatment Outcome
6.
Toxicol In Vitro ; 43: 58-61, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28599844

ABSTRACT

Vaccines against human papilloma virus (HPV) have been demonstrated to be very effective to prevent infection-related neoplasms. However, several reports describing heterogeneous post-vaccination phenomena have been published in last few years. The spectrum of these disorders includes both immune-mediated neurological diseases and neuropsychiatric functional disorders. Some researchers speculated about a genetic predisposition, but others hypothesized a role of adjuvants, including some metals and, particularly, aluminum. Here, we tested sixteen young girls developing somatoform and neurocognitive syndromes after the HPV immunization, through MELISA® test, detecting cell-mediated hypersensitivity to several metals. We found no association between these neurocognitive disorders and the results provided by this test; importantly, no patients showed hypersensitivity to aluminum, which is the inorganic adjuvant included in HPV vaccines. Thus, if aluminum played a role in the pathophysiology of musculoskeletal and neurocognitive disturbances occurring in some young girls after HPV immunization, that should recognize other mechanisms than the activation of aluminum-specific lymphocytes.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Aluminum Hydroxide/administration & dosage , Hypersensitivity/etiology , Papillomavirus Vaccines/adverse effects , Phosphates/administration & dosage , Adolescent , Adult , Child , Female , Humans , Hypersensitivity/blood , Hypersensitivity/immunology , Lymphocytes/immunology , Metals/administration & dosage , Metals/adverse effects , Neurocognitive Disorders/blood , Neurocognitive Disorders/etiology , Neurocognitive Disorders/immunology , Papillomavirus Vaccines/administration & dosage , Somatoform Disorders/blood , Somatoform Disorders/etiology , Somatoform Disorders/immunology , Young Adult
7.
Eur J Cancer ; 64: 62-73, 2016 09.
Article in English | MEDLINE | ID: mdl-27343714

ABSTRACT

BACKGROUND: Many paediatric brain tumour survivors (PBTS) suffer from neurocognitive impairments. Promising effects of neurofeedback (NF) on neurocognitive functioning have been reported, however research into NF for PBTS has not been conducted. We investigated the effects of NF on neurocognitive functioning in PBTS using a double-blind randomised placebo-controlled trial with a parallel-group design (Pediatric Research on Improving Speed, Memory, and Attention; the PRISMA study). METHODS: Eligible for inclusion were PBTS with neurocognitive complaints, aged 8-18 years, >2 years post-treatment. They were recruited from five medical centres in the Netherlands. A randomisation table assigned participants to 30 sessions (two per week) of either NF or placebo feedback (PF) (ratio 1:1). Participants, parents, trainers, and researchers handling the data were blinded to group assignment. Participants were assessed pre-, post- and 6 months post-training to determine whether NF training would lead to improved functioning as compared with PF training. Primary outcome measures were attention, processing speed, memory, executive functioning, visuomotor integration, and intelligence. Linear mixed models analyses were used to test differences between NF and PF training over time. RESULTS: A total of 82 children were enrolled (mean age 13.9 years, standard deviation = 3.2, 49% males); 80 participants were randomised (NF: n = 40, PF n = 40); 71 participants completed the training (NF: n = 34, PF: n = 37); 68 participants completed training and 6 months post-training assessment (NF: n = 33, PF: n = 35). Similar improvements were found over time for the two treatment groups on the primary outcomes (all p's > 0.15). CONCLUSION: Results indicated no specific treatment-effects of NF on neurocognitive functioning of PBTS.


Subject(s)
Brain Neoplasms/complications , Neurocognitive Disorders/therapy , Neurofeedback/methods , Survivors , Adolescent , Attention/physiology , Brain Neoplasms/psychology , Child , Cognition Disorders/therapy , Double-Blind Method , Executive Function/physiology , Female , Humans , Male , Memory/physiology , Netherlands , Neurocognitive Disorders/etiology , Neurocognitive Disorders/physiopathology , Reaction Time/physiology , Treatment Outcome
8.
Am J Clin Nutr ; 102(5): 1113-25, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26447156

ABSTRACT

BACKGROUND: Fetal alcohol spectrum disorders (FASDs) are conditions characterized by physical anomalies, neurodevelopmental abnormalities, and neurocognitive deficits, including intellectual, executive, and memory deficits. There are no specific biological treatments for FASDs, but rodent models have shown that prenatal or postnatal choline supplementation reduces cognitive and behavioral deficits. Potential mechanisms include phospholipid production for axonal growth and myelination, acetylcholine enhancement, and epigenetic effects. OBJECTIVE: Our primary goal was to determine whether postnatal choline supplementation has the potential to improve neurocognitive functioning, particularly hippocampal-dependent memory, in children with FASDs. DESIGN: The study was a double-blind, randomized, placebo-controlled pilot trial in children (aged 2.5-5 y at enrollment) with FASDs (n = 60) who received 500 mg choline or a placebo daily for 9 mo. Outcome measures were Mullen Scales of Early Learning (primary) and the elicited imitation (EI) memory paradigm (secondary). RESULTS: The administration proved feasible, and choline was well tolerated. Participants received a dose on 88% of enrolled days. The only adverse event linked to choline was a fishy body odor. Choline supplementation improved the secondary outcome (EI) only after immediate recall performance was controlled for, and the outcome was moderated by age. The treatment effect on EI items recalled was significant in the younger participants (2.5- to ≤4.0-y-olds); the young choline group showed an increase of 12-14 percentage points greater than that of the young placebo group on delayed recall measures during treatment. However, there was a marginal baseline difference in delayed item recall between the young choline and placebo groups as well as a potential ceiling effect for item recall, both of which likely contributed to the observed treatment effect. We also observed a trend toward a negative effect of choline supplementation on the immediate EI recall of ordered pairs; the young placebo group showed an increase of 8-17 percentage points greater than that of the choline group during treatment. There was an inverse relation between choline dose (in mg/kg) and memory improvement (P = 0.041); the data suggest that weight-adjusted doses may be a better alternative to a fixed dose in future studies. Limitations included trend-level baseline differences in performance, the post-hoc determination of age moderation, and potential ceiling effects for the memory measure. CONCLUSIONS: This pilot study suggests that an additional evaluation of choline supplementation as an intervention for memory functioning in children with FASDs is warranted. The observed interaction between age and choline's effect on EI suggests that potential sensitive periods should be considered in future work. This trial was registered at clinicaltrials.gov as NCT01149538.


Subject(s)
Behavioral Symptoms/prevention & control , Choline/therapeutic use , Dietary Supplements , Fetal Alcohol Spectrum Disorders/diet therapy , Neurocognitive Disorders/prevention & control , Nootropic Agents/therapeutic use , Behavioral Symptoms/etiology , Child, Preschool , Choline/administration & dosage , Choline/adverse effects , Dietary Supplements/adverse effects , Double-Blind Method , Feasibility Studies , Female , Fetal Alcohol Spectrum Disorders/physiopathology , Fetal Alcohol Spectrum Disorders/psychology , Humans , Intention to Treat Analysis , Learning , Longitudinal Studies , Male , Memory, Short-Term , Neurocognitive Disorders/etiology , Nootropic Agents/administration & dosage , Nootropic Agents/adverse effects , Odorants , Patient Compliance , Patient Dropouts , Pilot Projects
9.
Mil Med ; 180(9): 956-63, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26327547

ABSTRACT

Treating patient populations with significant psychiatric and neurocognitive symptomatology can present a unique clinical dilemma: progress in psychotherapy can be significantly fettered by cognitive deficits, whereas neurocognitive rehabilitation efforts can be ineffective because of psychiatric overlay. Application of mindfulness-based interventions to address either cognitive or psychiatric symptoms in isolation appears efficacious in many contexts; however, it remains unclear whether this type of intervention might help address simultaneous neurocognitive and psychiatric symptomatology. In a pre-post mixed methods design pilot study, nine Veterans with post-traumatic stress disorder (PTSD) and a history of mild traumatic brain injury with chronic cognitive complaints participated in Mindfulness-Based Stress Reduction (MBSR). Clinical interview, questionnaires, and attention and PTSD measures were administered immediately before, immediately after, and 3 months after MBSR completion. Qualitative and quantitative findings suggest high levels of safety, feasibility, and acceptability. Measurement of attention revealed significant improvement immediately following MBSR (p < 0.05, d = 0.57) and largely sustained improvement 3 months after completion of MBSR (p < 0.10, d = 0.48). Significant reduction in PTSD symptoms was found immediately after MBSR (p < 0.05, d = -1.56), and was sustained 3 months following MBSR completion (p < 0.05, d = -0.93). These results warrant a randomized controlled trial follow-up. Potential mechanisms for the broad effects observed will be explored.


Subject(s)
Brain Concussion/psychology , Mindfulness , Neurocognitive Disorders/therapy , Stress Disorders, Post-Traumatic/psychology , Stress Disorders, Post-Traumatic/therapy , Veterans/psychology , Adult , Attention , Humans , Middle Aged , Neurocognitive Disorders/etiology , Patient Satisfaction , Pilot Projects , Symptom Assessment
10.
Eur J Clin Nutr ; 69(6): 687-92, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25563739

ABSTRACT

BACKGROUND/OBJECTIVE: Functional cobalamin (Cbl; vitamin B12) deficiency (that is, high levels of the Cbl-dependent metabolites, methylmalonic acid (MMA) and homocysteine (HCys), despite normal serum Cbl values) is common in the elderly and is associated with neurocognitive abnormalities, but its cause is unknown. As only reduced Cbls are metabolically active, the possibility that functional Cbl deficiency is associated with disorders having biomarkers indicative of increased oxidative stress (oxidant risks) was considered. SUBJECTS/METHODS: A retrospective record review of community-dwelling adults evaluated over a 12-year period for Cbl deficiency in a primary care setting who had serum Cbl values ⩾400 pg/ml (n=170). RESULTS: When no oxidant risks were present, older subjects (⩾70 years) had higher metabolite values than younger individuals (<70 years). MMA values were even higher in the elderly when one oxidant risk was present and in younger subjects when two or more oxidant risks were present. Even at Cbl levels ⩾800 pg/ml, MMA values were increased in 73% of elderly subjects with at least one oxidant risk. HCys values were also higher in both age groups when at least two oxidant risks were present. Cyanocobalamin therapy decreased MMA and HCys values in 86 and 76% of subjects, respectively, with nonresponders more likely to have two or more oxidant risks. CONCLUSION: Functional Cbl deficiency is associated with disorders marked by increased oxidative stress particularly in the elderly; it occurs even when Cbl levels are high and is not consistently corrected with high-dose cyanocobalamin therapy. Thus, current approaches to recognizing and managing this disorder may be inadequate.


Subject(s)
Aging , Diabetes Mellitus/physiopathology , Neurocognitive Disorders/etiology , Oxidative Stress , Renal Insufficiency/physiopathology , Smoking/adverse effects , Vitamin B 12 Deficiency/etiology , Aged , Aged, 80 and over , Alcohol Drinking/adverse effects , Connecticut/epidemiology , Dietary Supplements , Female , Homocysteine/blood , Homocysteine/metabolism , Humans , Injections, Intramuscular , Male , Methylmalonic Acid/blood , Methylmalonic Acid/metabolism , Primary Health Care , Retrospective Studies , Risk Factors , Vitamin B 12/administration & dosage , Vitamin B 12/blood , Vitamin B 12/metabolism , Vitamin B 12/therapeutic use , Vitamin B 12 Deficiency/epidemiology , Vitamin B 12 Deficiency/metabolism , Vitamin B 12 Deficiency/therapy
11.
Transl Stroke Res ; 6(2): 125-32, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25167916

ABSTRACT

Primary spontaneous intracerebral hemorrhage (ICH) with secondary intraventricular hemorrhage (IVH) is an important clinical problem of which little is known. IVH and hydrocephalus are independent predictors of poor outcome in ICH. The aims of this study were, therefore, to establish a rat model of ICH with ventricular extension and investigate the occurrence of post-hemorrhagic chronic hydrocephalus and perihematomal tissue injury. Based on our previous rat model of IVH, we adjusted the injection coordinates and 200 µl autologous blood was stereotaxically infused into the right striatum (coordinates: 0.2 mm posterior, 2.2 mm lateral, and 5.0 mm depth to the bregma). At 24 h post-infusion, the rats produced reproducible hematoma and ventricle expansion, which closely mimics the ICH with ventricular extension in humans. Hematoma consequences and perihematomal tissue injury were evaluated on the acute phase. At 4 weeks, ventricular dilatation, brain tissue loss, hippocampus volume, and cortical thickness were measured with magnetic resonance imaging and neurocognitive function was assessed using the Morris water maze test. With blood infusion, the animals demonstrated brain edema, blood-brain barrier breakdown, and marked perihematomal tissue injury on the acute phase. At 4 weeks, the T2 images showed remarkable hydrocephalus and tissue loss, and the Morris water maze test revealed neurocognitive deficits. The present ICH with the ventricular extension rat model features characteristics of both ICH and IVH rat models, which could be used for extending our pathophysiological understanding of post-hemorrhagic chronic hydrocephalus and perihematomal tissue damage.


Subject(s)
Cerebral Hemorrhage/complications , Cerebral Hemorrhage/pathology , Hematoma/etiology , Hydrocephalus/etiology , Animals , Avoidance Learning/physiology , Blood Transfusion, Autologous/adverse effects , Brain Edema/etiology , Brain Injuries/etiology , Brain Injuries/pathology , Capillary Permeability , Cell Count , Cerebral Hemorrhage/etiology , Disease Models, Animal , Fluoresceins/metabolism , Functional Laterality , Hematoma/pathology , Male , Neurocognitive Disorders/etiology , Neuropsychological Tests , Rats , Rats, Sprague-Dawley , Reaction Time/physiology , Time Factors
12.
Eur J Neurol ; 14(12): 1378-82, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18028189

ABSTRACT

The intensity dependence of the auditory-evoked potentials (IDAP) is inversely related to serotonergic tone. Depression is frequently observed after stroke, associated with cognitive impairment and increased mortality. Aim of this study was to investigate the serotonergic tone in acute stroke patients by IDAP. Consecutive patients with an acute stroke admitted in our stroke unit were evaluated using clinical and instrumental examinations and compared with healthy controls. The IDAP was calculated as the linear amplitude/stimulus intensity function (ASF) slope, by measuring the peak-to-peak amplitude of Nl-P2 on four blocks of different stimulus intensities. Twenty patients were enrolled; 11 had a right brain infarction; nine had depressive symptoms (DS). The ASF slope of the auditory-evoked potentials was markedly increased in stroke patients compared with controls (P = 0.021). Stroke patients with DS had a significant steeper ASF slope than controls (P = 0.017). There was no statistical difference in ASF slope between stroke patients without DS and controls. Post-stroke depression pathophysiology is still debated. Our study suggests that in acute stroke patients with DS, there is a direct involvement of the serotonergic system, regardless the degree of disability and the site of the lesion.


Subject(s)
Auditory Perception/physiology , Evoked Potentials, Auditory/physiology , Neurocognitive Disorders/metabolism , Neurocognitive Disorders/physiopathology , Serotonin/metabolism , Stroke/physiopathology , Acoustic Stimulation , Acute Disease , Aged , Auditory Cortex/metabolism , Auditory Cortex/physiopathology , Auditory Pathways/metabolism , Auditory Pathways/physiopathology , Brain Stem/metabolism , Brain Stem/physiopathology , Cognition Disorders/etiology , Cognition Disorders/metabolism , Cognition Disorders/physiopathology , Depressive Disorder/etiology , Depressive Disorder/metabolism , Depressive Disorder/physiopathology , Electroencephalography , Female , Humans , Male , Middle Aged , Neurocognitive Disorders/etiology , Predictive Value of Tests , Raphe Nuclei/metabolism , Raphe Nuclei/physiopathology , Sensitivity and Specificity , Stroke/complications , Stroke/metabolism , Synaptic Transmission/physiology
13.
Arch Neurol ; 63(10): 1440-6, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17030661

ABSTRACT

OBJECTIVE: To characterize the clinical, radiological, and electrophysiological laboratory profiles and histological features of patients who developed cognitive impairment temporally associated with celiac disease. DESIGN: Case series. SETTING: Referral center. PATIENTS: Patients with the onset of progressive cognitive decline within 2 years of symptomatic onset or with a severe exacerbation of biopsy-proved adult celiac disease were identified from the Mayo Clinic medical records from January 1, 1970, to December 31, 2005. Patients were excluded if an alternate cause of their cognitive impairment was identified. RESULTS: Thirteen patients (5 women) were identified. The median age at cognitive impairment onset was 64 years (range, 45-79 years), which coincided with symptom onset or exacerbation of diarrhea, steatorrhea, and abdominal cramping in 5 patients. Amnesia, acalculia, confusion, and personality changes were the most common presenting features. The average initial Short Test of Mental Status score was 28 of a total of 38 (range, 18-34), which was in the moderately impaired range. The results of neuropsychological testing suggested a trend of a frontosubcortical pattern of impairment. Ten patients had ataxia, and 4 of them also had peripheral neuropathy. Magnetic resonance imaging of the head showed nonspecific T2 hyperintensities, and electroencephalography showed nonspecific diffuse slowing. Deficiencies in folate, vitamin B(12), vitamin E, or a combination were identified in 4 patients, yet supplementation did not improve their neurological symptoms. Three patients improved or stabilized cognitively with gluten withdrawal. A detailed histological analysis revealed nonspecific gliosis. CONCLUSIONS: A possible association exists between progressive cognitive impairment and celiac disease, given the temporal relationship and the relatively high frequency of ataxia and peripheral neuropathy, more commonly associated with celiac disease. Given the impact for potential treatment of similar cases, recognition of this possible association and additional studies are warranted.


Subject(s)
Brain/pathology , Brain/physiopathology , Celiac Disease/complications , Cognition Disorders/diagnosis , Cognition Disorders/etiology , Cognition Disorders/physiopathology , Aged , Ataxia/etiology , Ataxia/physiopathology , Avitaminosis/etiology , Disease Progression , Electroencephalography , Female , Food, Formulated , Gliosis/diagnosis , Gliosis/etiology , Gliosis/physiopathology , Glutens/adverse effects , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neurocognitive Disorders/etiology , Neurocognitive Disorders/physiopathology
14.
Eur J Neurol ; 13(7): 749-53, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16834705

ABSTRACT

A case of Marchiafava-Bignami (MB) syndrome with selective callosal involvement was evaluated by clinical examination and magnetic resonance imaging (MRI) in the acute phase and 6 months after the onset of symptoms; at the same time, the corticospinally and transcallosally mediated effects elicited by transcranial magnetic stimulation (TMS) were investigated. The first MRI study showed the presence of extensive abnormal signal intensity throughout the entire corpus callosum. After high-dose corticosteroid administration her symptoms rapidly resolved, in parallel with the reversion of MRI changes, except for severe cognitive impairment. Follow-up TMS examination revealed persistent transcallosal inhibition (TI) abnormalities. This report indicates that the measurement of TI during the course of MB syndrome is useful for evaluating functional changes to the corpus callosum, including their evaluation with time and after treatment and for elucidating the pathophysiology of MB syndrome.


Subject(s)
Corpus Callosum/pathology , Demyelinating Diseases/therapy , Neurocognitive Disorders/therapy , Transcranial Magnetic Stimulation/methods , Alcoholism/complications , Corpus Callosum/drug effects , Corpus Callosum/radiation effects , Demyelinating Diseases/etiology , Demyelinating Diseases/pathology , Diffusion Magnetic Resonance Imaging/methods , Electromyography/methods , Female , Humans , Middle Aged , Neurocognitive Disorders/etiology , Tomography, X-Ray Computed/methods , Vitamin B Complex/administration & dosage
15.
J Neurosci ; 24(7): 1780-91, 2004 Feb 18.
Article in English | MEDLINE | ID: mdl-14973249

ABSTRACT

A syndrome of motoric and neuropsychiatric symptoms comprising various elements, including chorea, hyperactivity, tics, emotional lability, and obsessive-compulsive symptoms, can occur in association with group A beta-hemolytic streptococcal (GABHS) infection. We tested the hypothesis that an immune response to GABHS can result in behavioral abnormalities. Female SJL/J mice were immunized and boosted with a GABHS homogenate in Freund's adjuvant, whereas controls received Freund's adjuvant alone. When sera from GABHS-immunized mice were tested for immunoreactivity to mouse brain, a subset was found to be immunoreactive to several brain regions, including deep cerebellar nuclei (DCN), globus pallidus, and thalamus. GABHS-immunized mice having serum immunoreactivity to DCN also had increased IgG deposits in DCN and exhibited increased rearing behavior in open-field and hole-board tests compared with controls and with GABHS-immunized mice lacking serum anti-DCN antibodies. Rearing and ambulatory behavior were correlated with IgG deposits in the DCN and with serum immunoreactivity to GABHS proteins in Western blot. In addition, serum from a GABHS mouse reacted with normal mouse cerebellum in nondenaturing Western blots and immunoprecipitated C4 complement protein and alpha-2-macroglobulin. These results are consistent with the hypothesis that immune response to GABHS can result in motoric and behavioral disturbances and suggest that anti-GABHS antibodies cross-reactive with brain components may play a role in their pathophysiology.


Subject(s)
Brain/immunology , Neurocognitive Disorders/etiology , Streptococcal Infections/complications , Streptococcal Infections/immunology , Streptococcus pyogenes/immunology , Animals , Bacterial Proteins/immunology , Behavior, Animal , Blotting, Western , Brain/pathology , Cerebellar Nuclei/immunology , Cerebellar Nuclei/pathology , Cross Reactions/immunology , Disease Models, Animal , Female , Globus Pallidus/immunology , Globus Pallidus/pathology , Immunization/methods , Immunoglobulin G/analysis , Immunoglobulin G/blood , Immunoglobulin G/metabolism , Membrane Proteins/biosynthesis , Mice , Motor Activity , Nerve Tissue Proteins/biosynthesis , Serologic Tests , Streptococcal Infections/pathology , Streptococcus pyogenes/chemistry , Synaptosomal-Associated Protein 25 , Thalamus/immunology , Thalamus/pathology
16.
Acta Otorrinolaringol Esp ; 53(5): 379-83, 2002 May.
Article in Spanish | MEDLINE | ID: mdl-12185873

ABSTRACT

Susac's syndrome is an extremely rare clinical manifestation characterized by the triad of fluctuating sensorineural hearing loss, sudden visual loss and encephalopathy. Probably underdiagnosed, it affects young women who start the clinical history with headache, visual and hearing disturbances, with neurological findings in MRI. With unknown aetiology, pathogenesis is based on arteriolar microinfarcts in retina, cochlea, and grey and white matter in the brain. Treatment is, as stated in the bibliography and our experience, intravenous high doses of steroids followed by oral steroids together with hyperbaric oxygen to minimize ischaemic lesions. Aspirin associate to nimodipine has been useful to date in the treatment of our patient. We present a case and review the existing literature.


Subject(s)
Cerebral Infarction/etiology , Cochlea/blood supply , Hearing Loss, Sensorineural/etiology , Infarction/diagnosis , Neurocognitive Disorders/etiology , Retinal Vessels/pathology , Vision Disorders/etiology , Adult , Anti-Inflammatory Agents/therapeutic use , Aspirin/therapeutic use , Combined Modality Therapy , Deafness/etiology , Diagnosis, Differential , Female , Fever/etiology , Hallucinations/etiology , Humans , Hyperbaric Oxygenation , Infarction/complications , Infarction/drug therapy , Infarction/therapy , Magnetic Resonance Imaging , Methylprednisolone/therapeutic use , Microcirculation , Nimodipine/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Syndrome
17.
J Neurol ; 241(2): 101-7, 1993 Dec.
Article in English | MEDLINE | ID: mdl-8138824

ABSTRACT

The clinical courses, cerebrospinal fluid (CSF) and serum copper concentrations and urinary copper excretions under different schemes of drug treatment in four patients with cerebral manifestations of Wilson's disease were monitored over 6-11 years. CSF copper concentration measurements were performed from the beginning of therapy onwards in three patients and from 16 months after initial treatment onwards in the fourth. CSF copper levels decreased slowly over the years in parallel with clinical improvements, and increased in one patient who interrupted therapy for 2 years. These findings confirm our hypothesis that the concentration of copper in the CSF is a valuable quantitative parameter reflecting the normalization of copper in the brain. Copper measurements during phases of initial neurological deterioration in two patients receiving D-penicillamine, and in one patient receiving D-penicillamine and zinc sulphate, revealed decreased free serum copper and CSF copper levels.


Subject(s)
Brain/metabolism , Chelation Therapy , Copper/cerebrospinal fluid , Hepatolenticular Degeneration/cerebrospinal fluid , Penicillamine/therapeutic use , Sulfates/therapeutic use , Zinc Compounds/therapeutic use , Adult , Ceruloplasmin/analysis , Chelation Therapy/adverse effects , Copper/analysis , Female , Hepatolenticular Degeneration/drug therapy , Hepatolenticular Degeneration/psychology , Humans , Male , Neurocognitive Disorders/etiology , Penicillamine/adverse effects , Zinc Sulfate
18.
Article in Russian | MEDLINE | ID: mdl-1333703

ABSTRACT

Clinical and experimental psychological studies (MMPI, Eisenks's questionnaire, methods by Luria and Kraepelin, types of attitude toward disease) carried out in 157 adults and children with progressive myodystrophies and amyotrophies revealed alterations in the neuropsychic sphere in 134 patients (85%). In the structure of borderline disorders, depressive disturbances prevailed (54.5%), and the asthenic and psychopathlike symptomatology could be seen. The use of the psychopharmacological and psychotherapeutic correction promoted regression of the psychopathological symptomatology in 76% of adults and in 84% of children.


Subject(s)
Anxiety Disorders/etiology , Neurocognitive Disorders/etiology , Neuromuscular Diseases/psychology , Neurotic Disorders/etiology , Adolescent , Adult , Anxiety Disorders/diagnosis , Anxiety Disorders/therapy , Autogenic Training , Child , Combined Modality Therapy , Depressive Disorder/diagnosis , Depressive Disorder/etiology , Depressive Disorder/therapy , Female , Humans , Hypochondriasis/diagnosis , Hypochondriasis/etiology , Hypochondriasis/therapy , Male , Middle Aged , Neurocognitive Disorders/diagnosis , Neurocognitive Disorders/therapy , Neuromuscular Diseases/complications , Neurotic Disorders/diagnosis , Neurotic Disorders/therapy , Psychological Tests , Psychotropic Drugs/therapeutic use
19.
Article in Russian | MEDLINE | ID: mdl-1338144

ABSTRACT

As many as 18 patients with a history of military service in Afghanistan, who suffered (7.2 years before on the average) commotion due to the explosion wave were examined. The vegetative status was studied by different methods including cardiointervalography, as was the patients' emotional and personality sphere. The data obtained were compared to those obtained in three control groups (practically healthy subjects; those who suffered a mild home craniocerebral injury; healthy subjects who fought in Afghanistan and were not victims to craniocerebral injury). The main group patients demonstrated noticeable changes in the vegetative tone, vegetative reactivity and vegetative supply to physical activity as well as a high level of anxiety, which forms vegetodystonia. Attempts were made to correct the psychovegetative syndrome by central electroanalgesia in the tranquilization mode (9-10 daily sessions). The lowering of the tension of regulatory body systems functioning and the reduction of anxiety and depression tendencies were recorded.


Subject(s)
Autonomic Nervous System Diseases/etiology , Brain Injuries/complications , Dystonia/etiology , Military Personnel , Vascular Diseases/etiology , Adult , Afghanistan , Autonomic Nervous System Diseases/psychology , Autonomic Nervous System Diseases/therapy , Blast Injuries/complications , Blast Injuries/psychology , Blast Injuries/therapy , Brain Injuries/psychology , Brain Injuries/therapy , Chronic Disease , Dystonia/psychology , Dystonia/therapy , Humans , Male , Neurocognitive Disorders/etiology , Neurocognitive Disorders/psychology , Neurocognitive Disorders/therapy , Syndrome , Transcutaneous Electric Nerve Stimulation , USSR , Vascular Diseases/psychology , Vascular Diseases/therapy , Warfare
SELECTION OF CITATIONS
SEARCH DETAIL